While the prices for a number of widely-used prescription drugs, including Humira, Cialis and Lyrica, rose twice the medical consumer price index between 2017-18, the Institute for Clinical and Economic Review (ICER) says the increases failed “to support a claim of additional clinical benefit,” CBS reports.
ICER released its report on unjustified price increases Oct. 8 this year.
“If new evidence emerges that shows a treatment may be more beneficial than what was previously understood, perhaps that new evidence could warrant some level of price increase,” ICER CMO David Rind said in a statement. “For seven of the nine drugs we reviewed, however, we found that the price increases lacked justification in new evidence.”
To read more on CBS, click here.